Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

[1]  N. Freedman,et al.  Personalized radiation dosimetry for PRRT—how many scans are really required? , 2020, EJNMMI Physics.

[2]  L. Cai,et al.  The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis , 2020, Journal of Cancer Research and Clinical Oncology.

[3]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Metz,et al.  NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy , 2020, The Journal of Nuclear Medicine.

[5]  S. Ben-Haim,et al.  Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management , 2020, EJNMMI Physics.

[6]  Ezgi Ilan,et al.  177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors , 2019, Neuroendocrinology.

[7]  P. Bernhardt,et al.  Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases , 2019, The Journal of Nuclear Medicine.

[8]  D. Bailey,et al.  Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy , 2018, EJNMMI Physics.

[9]  J. Beauregard,et al.  Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  J. Ramage,et al.  Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. , 2018, Seminars in oncology.

[11]  M. Ljungberg,et al.  Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy , 2018, EJNMMI Physics.

[12]  P. Summers,et al.  Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  H. Lundqvist,et al.  Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  A. Buck,et al.  Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days , 2018, The Journal of Nuclear Medicine.

[15]  Katarina Sjögreen Gleisner,et al.  Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force , 2017, EJNMMI Physics.

[16]  E. Krenning,et al.  Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors , 2017, Clinical Cancer Research.

[17]  Michael Ljungberg,et al.  Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[19]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[20]  P. Ruszniewski,et al.  ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms , 2016, Neuroendocrinology.

[21]  Eva Forssell-Aronsson,et al.  Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Anders Sundin,et al.  Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE , 2015, The Journal of Nuclear Medicine.

[23]  Michael Lassmann,et al.  The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[25]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Marion de Jong,et al.  Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  T. Visser,et al.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[33]  P Okunieff,et al.  Radiation dose-response of human tumors. , 1995, International journal of radiation oncology, biology, physics.